

**MARYLAND INSURANCE ADMINISTRATION
PHARMACEUTICAL SERVICES WORKGROUP – HB 754
MEETING #3
AGENDA**

**200 ST. PAUL PLACE
24th FLOOR HEARING ROOM
BALTIMORE, MARYLAND**

**Monday, April 29, 2019
10 AM**

**Call In 301-969-5227
Participant Code 611608824#**

I. Opening Remarks and Future Workgroup Meeting Schedule

Monday, May 6th, at 10am
Tuesday, June 11th, at 2pm
Tuesday, July 9th, at 2pm
Tuesday, August 13th, at 10am
Tuesday, September 10th, 2pm
Tuesday, October 8th, at 10am
Tuesday, November 19th at 10am

The next meeting will also be held at the MIA at 200 St. Paul Place, 24th Floor, Baltimore, Maryland 21202.

II. Discussion Topics

- 1) Questions Posed by the PCMA
 - a. With regard to the filing of contracts or amendments, can the price information submitted with the filing contain the payment formula only – rather than the actual prices? (eg, AWP – xx + \$y.yy dispensing fee).
 - b. With regard to the filing of contracts or amendments, please confirm that the information submitted to MIA will be protected under Gen. Prov. Art. 4-335 or other relevant provision of the Md. Public Information Act.
 - c. In Ins. Art. 15-1628.1(f)(4)(iii), there is a new requirement for a PBM to provide to a pharmacy, at time of appeal of a MAC pricing claim, the “mathematical calculation used to determine the maximum allowable cost”. This information is confidential and proprietary. It

is not shared with the pharmacy for fear it could lead to anti-competitive activity. There is nothing in the statute mandating the pharmacy maintain the confidentiality of this information; nor any penalties for failure to do so. What information does the MIA believe must be shared with a pharmacy under this section?

2) Maryland Provider Contract Requirements

- a. Existing statutory requirements for PBM related provider contracts (listed in the Provider Contract Laws Handout from Meeting #2)
 - i. Which of these provisions are appropriate in the PBM context?
 - ii. Which of these provisions are not appropriate in the PBM context?
- b. What should be included in the regulations to carry HB 754 into effect?

III. Other Issues for Discussion by Stakeholders?

IV. Wrap Up